Sequence for R-223 and administering physicianSequence for R-223 and administering physicianDescribe where in your clinical practice you generally integrate R-223. Who within (or external to) your institution is administering R-223 to the patient (eg, radiation oncologist, nuclear medicine, other)?
Basch E al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol 2014;32(30):3436-48. Abstract Blacksburg S et al. Integrating bone targeting radiopharmaceuticals into the management of patients with castrate-resistant prostate cancer with symptomatic bone metastases. Curr Treat Options Oncol 2015;16(3):325. Abstract Den RB et al. Effect of docetaxel on safety and efficacy of radium-223. Lancet Oncol 2014;15(12):1292-3. Abstract Hoskin P et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: A prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol 2014;15(12):1397-406. Abstract Lorente D et al. Sequencing of agents in castration-resistant prostate cancer. Lancet Oncol 2015;16(6):e279-92. Abstract Sartor O et al. Radium-223 dichloride experience in pretreated patients: Early access program setting. Proc ASCO 2015;Abstract 5063. Shore ND. Radium-223 dichloride for metastatic castration-resistant prostate cancer: The urologist's perspective. Urology 2015;85(4):717-24. Abstract |